Do I need regulatory approval to buy or sell a pharmacy business?

Do I need regulatory approval to buy or sell a pharmacy business?

Regulatory approval is a fundamental part of any pharmacy transaction and will often determine whether a transaction can proceed at all.

In England and Wales, a pharmacy must be registered with the General Pharmaceutical Council (GPhC), and the owner must be appropriately authorised. If the buyer is a company, it must appoint a superintendent pharmacist and ensure compliance with all regulatory standards from day one.

A key feature of a pharmacy business is usually its NHS contract, which enables a pharmacy/pharmacist to be included on the pharmaceutical list maintained by NHS England. This contract is typically the pharmacy’s primary source of income and plays a central role in the transaction.

What is the regulatory process when you buy or sell a pharmacy business?

The regulatory process depends on the structure of the deal:-

• Asset sale - the buyer must apply to NHS England for the transfer of any NHS contract. If the buyer is not already on the pharmaceutical list, they must also submit a fitness to practise application. This will apply to first-time buyers and new corporate subsidiaries.
  
  

Once the fitness application has been approved, NHS England will consider the contract transfer. If consent is granted, there is a statutory appeal period before completion can take place.

This process takes at least three months, and often longer, so it is critical that it is started early and carefully managed.

• Share sale – provided that any NHS contract is in the name of the target business and not an individual director or shareholder, then no transfer of the NHS contract is required, as it remains with the company being acquired. This means no prior NHS consent is needed before completion, which can significantly streamline the process.
  
  

The buyer must notify NHS England of changes (such as directors or the superintendent pharmacist), but this can be done on or shortly after completion.

In all cases, the GPhC must be notified of any change of control, although this is usually a post-completion step and does not delay the transaction.

Regulatory compliance is critical. Failure to undertake appropriate due diligence and obtain the necessary approvals, or delays in doing so, can result in a buyer completing the purchase but being unable to lawfully operate the pharmacy or receive NHS income. Careful coordination of the legal transaction and regulatory applications is therefore essential.

Wake Smith’s specialist Healthcare and Wellbeing team have extensive experience of providing pharmacies, doctors surgeries and dental practices with all the legal support they require.  To find out more, please contact us today.

Should I structure the deal as an asset sale or a share sale when buying or selling a pharmacy?

Choosing between an asset sale and a share sale is often one of the most contemplated decisions in a pharmacy transaction. In the pharmaceutical sector, the decision is heavily influenced by regulatory requirements, particularly the treatment of the NHS contract, as well as risk and timing considerations.

What happens in an asset sale when buying or selling a pharmacy?

• The buyer acquires the business and its assets directly. This allows greater control over what is acquired and can reduce exposure to historic liabilities.

• However, this structure is usually more complex in the pharmacy sector:-

• any NHS contract must be transferred, and this process often comprises its own complications;
• a “fitness to practise” application may be required;
• there is a minimum three-month regulatory timetable, often longer;
• a new GPhC premises registration is typically needed; and
• employees usually transfer automatically under legislation, so Employment / HR teams are crucial during this type of transaction.

What happens in a share sale when buying or selling a pharmacy?

• The buyer acquires the shares in the company that operates the pharmacy. The legal entity remains the same, so provided any NHS contract is properly registered in the name of the target business:-

• any NHS contract with NHS England stays in place without transfer or prior approval;
• the GPhC registration continues uninterrupted; and
• the transaction is often quicker to complete than an asset sale

• However, the buyer acquires the company “as is”, including all historic liabilities of the business. This makes thorough legal, financial, and regulatory due diligence essential, along with appropriate contractual protections to limit the impact of any historic concerns.

In practice, the position with the NHS contract is often the decisive factor:-

• if speed, certainty, and continuity are key, a share sale is often preferred;
• if limiting liability is the priority, an asset sale may be more appropriate, albeit slower and more complex.

Unlike many other sectors, share sales in pharmacy transactions are frequently more straightforward.

We advise clients at an early stage on the most suitable structure, taking into account regulatory requirements, risk allocation, timing, and commercial objectives, and we manage the process from beginning to end to ensure a smooth and compliant transaction.

Wake Smith’s specialist Healthcare and Wellbeing team have extensive experience of providing pharmacies, doctors surgeries and dental practices with all the legal support they require.  To find out more, please contact us online or call us on 0114 266 6660

Published 24/04/2026